TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS

NOVEMBER 01, 2007

Teva Pharmaceutical Industries Ltd has resolved its patent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-based generic drug maker to enter the US market with its generic versions of 3 GSK diabetes drugs: Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate and metformin HCl), and Avandaryl (rosiglitazone maleate and glimepiride) oral tablets. Although details of the settlement were held confidential by both parties, it was disclosed that Teva could begin US marketing of the GSK drugs late in the first quarter of 2012. GSK filed several lawsuits challenging Teva?s plans to market generic versions of its drugs, and a trial in federal court had been scheduled to begin in August.




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.